Scienture Holdings shares rise 11.23% intraday after FDA approval of high-dose naloxone nasal spray with $154M market potential and orange book-listed patent.

Scienture Holdings surged 11.23% in intraday trading, with the company announcing the approval of Rezenopy™ 10mg hydrochloride naloxone nasal spray's Orange Book-listed patent, which is FDA-approved for the highest-dose naloxone nasal spray for opioid overdose emergencies. The product targets the US naloxone market with $154 million annual sales and 9.3 million units sold annually, highlighting its commercial potential. Additionally, the company signed an exclusive agreement with Summit Biosciences in March 2025 for sales, marketing, and distribution of Rezenopy™ in the US through its commercial infrastructure.